{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:35:27Z","timestamp":1789500927748,"version":"build-2803163510"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,12,21]],"date-time":"2009-12-21T00:00:00Z","timestamp":1261353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc electrophysiol"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:p>\n                    <jats:bold>\n                      Ibutilide Guided CFAE Ablation.\n                      <jats:italic>Introduction:<\/jats:italic>\n                    <\/jats:bold>\n                    While able to achieve clinical success, the current step\u2010wise approach to persistent atrial fibrillation (AF) ablation requires considerable \u201csubstrate\u201d ablation and frequently mandates multiple procedures to address consequent atrial tachycardias (ATs). An alternative strategy minimizing the amount of ablation while maintaining clinical success would be desirable. We hypothesize that intraprocedural administration of a low\u2010dose antiarrhythmic drug (AAD) during AF will organize areas of passive activation and not affect areas critical to AF maintenance, thereby potentially minimizing the ablation lesion set.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Methods and Results:<\/jats:italic>\n                    <\/jats:bold>\n                    Eleven patients (age = 55 \u00b1 6 years; LA = 48 \u00b1 15 mm; median AF duration = 3 years) with persistent AF undergoing catheter ablation were enrolled in this exploratory prospective observational study. After pulmonary vein (PV) isolation, a mean cycle length (mCL) map was created and areas with mCL &lt;120 ms were considered to represent complex fractionated atrial electrograms (CFAE). Ibutilide (0.25\u20131.0 mg) was then administered and a second mCL map created. Ablation lesions were placed at CAFE sites identified after ibutilide administration. Activation and\/or entrainment mapping was employed to address ATs. The endpoint of ablation was achieving sinus rhythm. The average LA mCL increased (146 vs 165 ms, P = 0.01) and the LA CFAE surface area decreased after ibutilide administration. Additional ablation organized AF to either sinus rhythm or AT in 10\/11 (91%) patients. After a median follow up of 455 days, 8 of 11 (72%) patients were free from AF. Three patients underwent a repeat ablation procedure (average 1.27 ablations\/patient).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Conclusions:<\/jats:italic>\n                    <\/jats:bold>\n                    Ibutilide administration may organize atrial activity and facilitate AF termination during ablation while minimizing the ablation lesion set.\n                    <jats:italic>(J Cardiovasc Electrophysiol, Vol. 21, pp. 608\u2010616, June 2010)<\/jats:italic>\n                  <\/jats:p>","DOI":"10.1111\/j.1540-8167.2009.01671.x","type":"journal-article","created":{"date-parts":[[2009,12,21]],"date-time":"2009-12-21T14:16:05Z","timestamp":1261404965000},"page":"608-616","source":"Crossref","is-referenced-by-count":44,"title":["Intraprocedural Use of Ibutilide to Organize and Guide Ablation of Complex Fractionated Atrial Electrograms: Preliminary Assessment of a Modified Step\u2010Wise Approach to Ablation of Persistent Atrial Fibrillation"],"prefix":"10.1111","volume":"21","author":[{"given":"SHELDON M.","family":"SINGH","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDRE","family":"D\u2019AVILA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEVEN J.","family":"KIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRISTOPHER","family":"HOUGHTALING","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SRINIVAS R.","family":"DUKKIPATI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VIVEK Y.","family":"REDDY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,5,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.12.054"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.10.044"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2008.01189.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2008.09.016"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.10.054"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2008.01133.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2008.10.046"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2008.01189.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2005.00308.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1540-8167.2004.03402.x"},{"key":"e_1_2_6_12_2","first-page":"e257","article-title":"American College of Cardiology\/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society","volume":"114","author":"Fuster V","year":"2006","journal-title":"Circulation"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.5.1588"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2008.01145.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2008.01148.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2008.01393.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2008.04.021"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.107.748780"}],"container-title":["Journal of Cardiovascular Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1540-8167.2009.01671.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1540-8167.2009.01671.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T06:46:23Z","timestamp":1698907583000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1540-8167.2009.01671.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,17]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1540-8167.2009.01671.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1540-8167.2009.01671.x","archive":["Portico"],"relation":{},"ISSN":["1045-3873","1540-8167"],"issn-type":[{"value":"1045-3873","type":"print"},{"value":"1540-8167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,17]]}}}